ChromaDex Corporation (NASDAQ:CDXC) Q2 2023 Earnings Call Transcript August 9, 2023 4:30 PM ET Company Participants Kendall Knysch - Director, Media Relations Rob Fried - Chief Executive Officer Brianna Gerber - Chief Financial Officer Conference Call Participants Ram Selvaraju - H.C. Wainwright Jeff Van Sinderen - B. Riley Mitch Pinheiro - Sturdivant Sean McGowan - ROTH MKM Operator Hello. My name is Aisha and I'll be your conference operator today. At this time, I'd like to welcome everyone to the ChromaD ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 Commission File Number: 001-37752 CHROMADEX CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 26-2940963 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 10900 Wilshire Blvd. Suite 600, Los Angeles, California 90024 (A ...

ChromaDex Corporation (NASDAQ:CDXC) Q1 2023 Results Conference Call May 10, 2023 4:30 PM ET Company Participants Kendall Knysch - Director, Media Relations Rob Fried - Chief Executive Officer Brianna Gerber - Chief Financial Officer Andrew Shao - Senior Vice President-Scientific and Regulatory Affairs Conference Call Participants Jeff Van Sinderen - B. Riley Ram Selvaraju - H.C. Wainwright Mitch Pinheiro - Sturdivant Sean McGowan - ROTH MKM JP Mark - Farmhouse Equity Research Jeff Cohen - Ladenburg Thalmann ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 Commission File Number: 001-37752 CHROMADEX CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 26-2940963 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 10900 Wilshire Blvd. Suite 600, Los Angeles, California 90024 ( ...

Investor Presentation Rob Fried Chief Executive Officer Brianna Gerber Chief Financial Officer Nasdaq: CDXC | March 2023 SAFE HARBOR STATEMENT This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forwardlooking statements reflect the current view about future events. State ...

ChromaDex Corporation (NASDAQ:CDXC) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants Tom Shumaker – LifeSci Advisors, Agency IR Counsel Rob Fried – Chief Executive Officer Brianna Gerber – Chief Financial Officer Andrew Shao – Senior Vice President-Scientific and Regulatory Affairs Conference Call Participants Mitch Pinheiro – Sturdivant Jeff Van Sinderen – B. Riley Ram Selvaraju – H.C. Wainwright Destiny Hance – Ladenburg Thalmann Sean McGowan – Roth MKM Bill Dezellem – Tieton ...

公司概况 - ChromaDex是一家全球生物科学公司，致力于健康老龄化[233] 产品信息 - 公司开发的Niagen®是NAD+前体烟酰胺核糖苷的创新产品[234] - 公司主要销售Tru Niagen®，在2022年实现总净销售额为7205万美元，同比增长7%[255] - Tru Niagen®的电子商务销售增长稳定，2022年比2021年增长了800万美元[256] 合作与协议 - 公司与NHSc签订供应协议，NHSc同意以1.31美元的价格购买380万股普通股[243] 财务表现 - 公司2022年实现营业收入4279.7万美元，净亏损1654万美元[253] - 公司2022年认可的员工保留税收抵免约210万美元[248] - 公司2022年总净销售额增长460万美元，主要受到Tru Niagen®和A.S. Watson's销售增长的推动[256] - 公司2022年销售和营销费用2831.3万美元，研发费用482.6万美元，总体营业费用较2021年有所下降[253] - 公司2022年基本和摊薄每股亏损为0.24美元[253] 部门表现 - 2022年，公司的成分部门整体净销售额较2021年增加了130万美元，增长18%[257] - 2022年，分析参考标准和服务部门的净销售额较2021年略有下降，主要是由于2022年对研发服务需求的下降[258] 成本分析 - 2022年，总成本中的销售成本占净销售额的比例较2021年增加了3%[259] - 消费品部门的销售成本占净销售额的比例在2022年与2021年相比基本保持不变，仅增加了1%[260] - 成分部门的销售成本占净销售额的比例在2022年较2021年增加了7%[261] - 分析参考标准和服务部门的销售成本占净销售额的比例在2022年较2021年增加了10%[262] 毛利分析 - 2022年，总毛利较2021年增加了130万美元，增长3%[263] - 消费品部门的总毛利较2021年增加了4%[264] 销售和营销费用 - 销售和营销费用中，消费品部门的销售和营销费用占净销售额的比例在2022年与2021年相比降低了3%[265] 研发费用 - 研发费用中，消费品部门的研发费用较2021年增加了23%[268] 资本需求 - 公司拥有 ATM Facility，截至2022年12月31日，该设施还剩下约4780万美元可用[287] - 公司未来的资本需求取决于多种因素，包括运营现金流、增加销售额、提高毛利润、降低销售和行政费用、继续发展客户关系以及成功推广新产品[288] 股息政策 - 公司目前没有宣布或支付任何现金股息，未来的股息政策取决于董事会的决定，以及公司的盈利、债务服务和资本需求等因素[289]

ChromaDex Corporation (NASDAQ:CDXC) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Tom Shumaker - Investor Relations Robert Fried - Chief Executive Officer Brianna Gerber - Interim Chief Financial Officer Conference Call Participants Jeff Cohen - Ladenburg Thalmann Sean McGowan - ROTH Capital Jeff Van Sinderen - B. Riley Mitchell Pinheiro - Sturdivant & Company Brian Nagel - Oppenheimer Operator Ladies and gentlemen, thank you for standing by, and welcome to ChromaDex Corp ...

ChromaDex Corporation (NASDAQ:CDXC) Q2 2022 Results Conference Call August 10, 2022 4:30 AM ET Company Participants Heather Van Blarcom - Senior Vice President of Legal and Corporate Secretary Robert Fried - Chief Executive Officer Kevin Farr - Chief Financial Officer Brianna Gerber - Vice President of Finance and Investor Relations Conference Call Participants Brian Nagel - Oppenheimer Mitchell Pinheiro - Sturdivant Raghuram Selvaraju - H.C. Wainwright Sean McGowan - ROTH Capital Jeffrey Cohen - Ladenburg ...

| --- | --- | |--------------------------|-------| | | | | ChromaDex | | | | | | | | | | | | Earnings Conference Call | | | | | | First Quarter 2022 | | Rob Fried Chief Executive Officer Frank Jaksch Co-Founder / Executive Chairman Kevin Farr Chief Financial Officer Nasdaq: CDXC | May 2022 SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain "forward-looking statements" within the meaning of Section 27A of the Securitie ...